Pangenomic Health Inc.
NARA
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -63.27% | -70.45% | -74.30% | -63.50% | 9.27% |
| Gross Profit | 63.27% | 70.45% | 74.30% | 63.50% | -9.27% |
| SG&A Expenses | -41.65% | -74.84% | -74.03% | -42.77% | -73.87% |
| Depreciation & Amortization | -34.78% | 0.00% | 4.55% | 4.55% | 4.55% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.18% | -74.34% | -80.51% | -47.50% | -64.97% |
| Operating Income | 51.18% | 74.34% | 80.51% | 47.50% | 64.97% |
| Income Before Tax | 51.46% | -159.56% | 79.26% | 94.11% | 61.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.46% | -159.56% | 79.26% | 94.11% | 61.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.46% | -159.56% | 79.26% | 94.11% | 61.07% |
| EBIT | 51.18% | 74.34% | 80.51% | 47.50% | 64.97% |
| EBITDA | 51.35% | 74.61% | 80.77% | 47.66% | 65.19% |
| EPS Basic | 84.96% | 7.85% | 80.51% | 95.53% | 75.23% |
| Normalized Basic EPS | 84.55% | 90.50% | 80.52% | 58.31% | 75.77% |
| EPS Diluted | 84.96% | 7.85% | 80.51% | 95.53% | 75.23% |
| Normalized Diluted EPS | 84.55% | 90.50% | 80.52% | 58.31% | 75.77% |
| Average Basic Shares Outstanding | 222.15% | 181.71% | 6.43% | 31.88% | 57.23% |
| Average Diluted Shares Outstanding | 222.15% | 181.71% | 6.43% | 31.88% | 57.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |